Drug development

Why drugs fail: of mice and men revisited.
[11234873] Clin Cancer Res 7(2): 229-30 (2001)

What are the reasons for negative phase III trials of molecular-target-based drugs?
[15504242] Cancer Sci 95(10): 772-6 (2004)

Deorphanization of novel peptides and their receptors.
[20446073] AAPS J 12(3): 378-84 (2010)

Modelling and PBPK simulation in drug discovery.
[19280352] AAPS J 11(1): 155-66 (2009)

New paradigms and tools in drug design for pain and addiction.
[17025262] AAPS J 8(3): E450-60 (2006)

Requirements for a lead compound to become a clinical candidate.
[19091004] BMC Neurosci 9 Suppl 3(-): S7 (2008)

In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling.
[17549047] Br J Pharmacol 152(1): 9-20 (2007)

In silico pharmacology for drug discovery: applications to targets and beyond.
[17549046] Br J Pharmacol 152(1): 21-37 (2007)

Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors.
[9846630] Br J Pharmacol 125(5): 924-47 (1998)

Therapeutic targets: progress of their exploration and investigation of their characteristics.
[16714488] Pharmacol Rev 58(2): 259-79 (2006)

Impact of drug transporter studies on drug discovery and development.
[12869659] Pharmacol Rev 55(3): 425-61 (2003)

Role of pharmacokinetics and metabolism in drug discovery and development.
[9443165] Pharmacol Rev 49(4): 403-49 (1997)

Prodrug and antedrug: two diametrical approaches in designing safer drugs.
[12009024] Arch Pharm Res 25(2): 111-36 (2002)

Metabolism-based anticancer drug design.
[10615856] Arch Pharm Res 22(6): 533-41 (1999)

Promiscuous drugs compared to selective drugs (promiscuity can be a virtue).
[15854222] BMC Clin Pharmacol 5(1): 3 (2005)

Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies.
[20046568] MAbs 1(1): 2-11 (2009)

Philosophy of new drug discovery.
[3534537] Microbiol Rev 50(3): 259-79 (1986)

Quantitative systems-level determinants of human genes targeted by successful drugs.
[18083776] Genome Res 18(2): 206-13 (2008)

Efficient drug lead discovery and optimization.
[19317443] Acc Chem Res 42(6): 724-33 (2009)

Identification of direct protein targets of small molecules.
[21077692] ACS Chem Biol 6(1): 34-46 (2011)

Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One.
[19112665] ACS Chem Biol 3(11): 677-692 (2008)

The impact of genomic and proteomic technologies on the development of new cancer drugs.
[12401677] Ann Oncol 13 Suppl 4(-): 115-24 (2002)

Assessing oncologic benefit in clinical trials of immunotherapy agents.
[20237004] Ann Oncol 21(10): 1944-51 (2010)

Towards the optimal screening collection: a synthesis strategy.
[18080276] Angew Chem Int Ed Engl 47(1): 48-56 (2008)

The value of natural products to future pharmaceutical discovery.
[18033577] Nat Prod Rep 24(6): 1225-44 (2007)

Natural products to drugs: natural product derived compounds in clinical trials.
[15806196] Nat Prod Rep 22(2): 162-95 (2005)

Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries.
[18663392] Nat Prod Rep 25(4): 719-37 (2008)

Changing requirements for evaluation of pharmacologic agents.
[15060209] Pediatrics 113(4 Suppl): 1128-32 (2004)

Specificity in computational protein design.
[20670934] J Biol Chem 285(41): 31095-9 (2010)

Discovering the targets of drugs via computational systems biology.
[21566122] J Biol Chem 286(27): 23653-8 (2011)

Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases.
[20147746] J Biol Chem 285(15): 11061-7 (2010)

Transcriptional switches: chemical approaches to gene regulation.
[20147748] J Biol Chem 285(15): 11033-8 (2010)

Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
[21524390] Discov Med 11(59): 367-75 (2011)

Analysis of information flows in interaction networks: implication for drug discovery and pharmacological research.
[21356168] Discov Med 11(57): 133-43 (2011)

Development of anti-cancer drugs.
[21034677] Discov Med 10(53): 355-62 (2010)

Therapeutic selectivity and the multi-node drug target.
[20040268] Discov Med 8(43): 185-90 (2009)

Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development.
[20132213] Br J Pharmacol 159(7): 1367-73 (2010)

Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development.
[19775279] Br J Pharmacol 159(1): 34-48 (2010)

Chemogenomic approaches to rational drug design.
[17533416] Br J Pharmacol 152(1): 38-52 (2007)

Origin and evolution of high throughput screening.
[17603542] Br J Pharmacol 152(1): 53-61 (2007)

Effects of NXY-059 in experimental stroke: an individual animal meta-analysis.
[19422398] Br J Pharmacol 157(7): 1157-71 (2009)

To scale or not to scale: the principles of dose extrapolation.
[19508398] Br J Pharmacol 157(6): 907-21 (2009)

Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials.
[21415927] PLoS One 6(3): e16633 (2011)

Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma.
[21283735] PLoS One 6(1): e14573 (2011)

Inhibition of HERG potassium channels by celecoxib and its mechanism.
[22039467] PLoS One 6(10): e26344 (2011)

Conformational diversity and computational enzyme design.
[20829099] Curr Opin Chem Biol 14(5): 676-82 (2010)

Privileged scaffolds for library design and drug discovery.
[20303320] Curr Opin Chem Biol 14(3): 347-61 (2010)

Residue-specific incorporation of non-canonical amino acids into proteins: recent developments and applications.
[21071259] Curr Opin Chem Biol 14(6): 774-80 (2010)

Contemporary strategies for the stabilization of peptides in the alpha-helical conformation.
[18793750] Curr Opin Chem Biol 12(6): 692-7 (2008)

Peptidomimetics, a synthetic tool of drug discovery.
[18423417] Curr Opin Chem Biol 12(3): 292-6 (2008)

New trends for metal complexes with anticancer activity.
[18155674] Curr Opin Chem Biol 12(2): 197-206 (2008)

How is the biocompatibilty of dental biomaterials evaluated?
[17468726] Med Oral Patol Oral Cir Bucal 12(3): E258-66 (2007)

Drug research: marketing before evidence, sales before safety.
[20467552] Dtsch Arztebl Int 107(16): 277-8 (2010)

The use of biodiversity as source of new chemical entities against defined molecular targets for treatment of malaria, tuberculosis, and T-cell mediated diseases--a review.
[16302058] Mem Inst Oswaldo Cruz 100(6): 475-506 (2005)

Reviewing ligand-based rational drug design: the search for an ATP synthase inhibitor.
[21954360] Int J Mol Sci 12(8): 5304-18 (2011)

Multi-step usage of in vivo models during rational drug design and discovery.
[21731440] Int J Mol Sci 12(4): 2262-74 (2011)

Drug discovery without a molecular target: the road less traveled.
[17187477] Expert Rev Mol Diagn 7(1): 1-4 (2007)

Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development.
[21438803] Expert Rev Cardiovasc Ther 9(3): 265-77 (2011)

Early human studies of investigational agents: dose or microdose?
[19523010] Br J Clin Pharmacol 67(3): 277-9 (2009)

Drug discovery and development for neglected diseases: the DNDi model.
[21552487] Drug Des Devel Ther 5(-): 175-81 (2011)

Prediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates.
[15713739] Bioinformatics 21(10): 2145-60 (2005)

Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets.
[17925305] Bioinformatics 24(3): 389-95 (2008)

Carcinogenicity assessments of biotechnology-derived pharmaceuticals: a review of approved molecules and best practice recommendations.
[20472697] Toxicol Pathol 38(4): 522-53 (2010)

Inbred strains should replace outbred stocks in toxicology, safety testing, and drug development.
[20562325] Toxicol Pathol 38(5): 681-90 (2010)

Biomarkers of endothelial cell activation serve as potential surrogate markers for drug-induced vascular injury.
[20716788] Toxicol Pathol 38(6): 856-71 (2010)

An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development.
[19893055] Toxicol Pathol 38(1): 51-61 (2010)

Safety assessment considerations and strategies for targeted small molecule cancer therapeutics in drug discovery.
[19907054] Toxicol Pathol 38(1): 165-8 (2010)

Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretation.
[19915137] Toxicol Pathol 38(1): 43-50 (2010)

Predictive toxicology approaches for small molecule oncology drugs.
[20075108] Toxicol Pathol 38(1): 148-64 (2010)

Biomarkers in development of psychotropic drugs.
[21842620] Dialogues Clin Neurosci 13(2): 225-34 (2011)

Mechanism targeted discovery of antitumor marine natural products.
[15279579] Curr Med Chem 11(13): 1725-56 (2004)

Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery.
[20088756] Curr Med Chem 17(8): 759-66 (2010)

Recent trends in targeted anticancer prodrug and conjugate design.
[18691040] Curr Med Chem 15(18): 1802-26 (2008)

Building a pharmacological lexicon: small molecule discovery in academia.
[17405872] Mol Pharmacol 72(1): 1-7 (2007)

Bridging the gap: facilities and technologies for development of early stage therapeutic mAb candidates.
[21822050] MAbs 3(5): 440-52 (2011)

Metrics for antibody therapeutics development.
[20930555] MAbs 2(6): 695-700 (2010)

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies.
[20421713] MAbs 2(3): 233-55 (2010)

Role of open chemical data in aiding drug discovery and design.
[21426107] Future Med Chem 2(6): 903-7 (2010)

Extracting molecular information from African natural products to facilitate unique African-led drug-discovery efforts.
[21446839] Future Med Chem 3(3): 257-61 (2011)

Future inhaled drugs by virtual innovation: allergen delivery inhibitors.
[21942246] Future Med Chem 3(13): 1567-70 (2011)

The importance of patent sharing in neglected disease drug discovery.
[21879838] Future Med Chem 3(11): 1331-4 (2011)

Drug repositioning in the treatment of malaria and TB.
[21879845] Future Med Chem 3(11): 1413-26 (2011)

Electron-density descriptors as predictors in quantitative structure--activity/property relationships and drug design.
[21707400] Future Med Chem 3(8): 969-94 (2011)

Renaissance of ion channel research and drug discovery by patch clamp automation.
[21426196] Future Med Chem 2(5): 691-5 (2010)

Emerging new technology: QSAR analysis and MO Calculation to characterize interactions of protein kinase inhibitors with the human ABC transporter, ABCG2 (BCRP).
[20208390] Drug Metab Pharmacokinet 25(1): 72-83 (2010)

Microdosing for reduction of the time and resources for drug development.
[17965515] Drug Metab Pharmacokinet 22(5): 327 (2007)

Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases.
[20210752] Curr Drug Targets 11(3): 264-78 (2010)

Target validation: linking target and chemical properties to desired product profile.
[21401506] Curr Top Med Chem 11(10): 1275-83 (2011)

Emerging methods for ensemble-based virtual screening.
[19929833] Curr Top Med Chem 10(1): 3-13 (2010)

The pilot phase of the NIH Chemical Genomics Center.
[19807664] Curr Top Med Chem 9(13): 1181-93 (2009)

Integration of small-molecule discovery in academic biomedical research.
[20687180] Mt Sinai J Med 77(4): 350-7 (2010)

Using NMR approaches to drive the search for new CNS therapeutics.
[20571972] Curr Opin Investig Drugs 11(7): 771-8 (2010)

New perspectives on innovative drug discovery: an overview.
[21092716] J Pharm Pharm Sci 13(3): 450-71 (2010)

A medicinal chemist's guide to molecular interactions.
[20345171] J Med Chem 53(14): 5061-84 (2010)

Systems approaches to polypharmacology and drug discovery.
[20443163] Curr Opin Drug Discov Devel 13(3): 297-309 (2010)

Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.
[17921028] Nucl Med Biol 34(7): 757-78 (2007)

Lessons learnt from assembling screening libraries for drug discovery for neglected diseases.
[18064617] ChemMedChem 3(3): 435-44 (2008)

Modelling and simulation as research tools in paediatric drug development.
[21246352] Eur J Clin Pharmacol 67 Suppl 1(-): 75-86 (2011)

Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).
[19405524] Bioconjug Chem 20(10): 1816-35 (2009)

Designing ligands to bind proteins.
[16817982] Q Rev Biophys 38(4): 385-95 (2005)

High Throughput Techniques for Discovering New Glycine Receptor Modulators and their Binding Sites.
[19949449] Front Mol Neurosci 2(-): 17 (2009)

How many good antidepressant medications have we missed?
[15309041] J Psychiatry Neurosci 29(4): 248-9 (2004)

Custom-designed proteins as novel therapeutic tools? The case of arrestins.
[20412604] Expert Rev Mol Med 12(-): e13 (2010)

Introduction of new tools for chemical biology research on microbial metabolites.
[20530900] Biosci Biotechnol Biochem 74(6): 1135-40 (2010)

Virtual screening of chemical libraries.
[15602552] Nature 432(7019): 862-5 (2004)

Identifying genomic and developmental causes of adverse drug reactions in children.
[21121777] Pharmacogenomics 11(11): 1591-602 (2010)

Create a translational medicine knowledge repository--research downsizing, mergers and increased outsourcing have reduced the depth of in-house translational medicine expertise and institutional memory at many pharmaceutical and biotech companies: how will they avoid relearning old lessons?
[21569250] J Transl Med 9(-): 56 (2011)

Analysis of in vitro bioactivity data extracted from drug discovery literature and patents: Ranking 1654 human protein targets by assayed compounds and molecular scaffolds.
[21569515] J Cheminform 3(1): 14 (2011)

CoMSIA and docking study of rhenium based estrogen receptor ligand analogs.
[17280694] Steroids 72(3): 247-60 (2007)

Molecular dynamics simulations and drug discovery.
[22035460] BMC Biol 9(-): 71 (2011)

Molecular similarity: a key technique in molecular informatics.
[15534697] Org Biomol Chem 2(22): 3204-18 (2004)

Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach.
[17229415] Chem Biol Interact 171(2): 165-76 (2008)

Docking and chemoinformatic screens for new ligands and targets.
[19733475] Curr Opin Biotechnol 20(4): 429-36 (2009)

Application of an integrated physical and functional screening approach to identify inhibitors of the Wnt pathway.
[19888210] Mol Syst Biol 5(-): 315 (2009)

Validating cancer drug targets through chemical genetics.
[20708654] Biochim Biophys Acta 1806(2): 251-7 (2010)

Beyond directed evolution--semi-rational protein engineering and design.
[20869867] Curr Opin Biotechnol 21(6): 734-43 (2010)

Optimizing non-natural protein function with directed evolution.
[21185770] Curr Opin Chem Biol 15(2): 201-10 (2011)

Chemoenzymatic methods for site-specific protein modification.
[21030291] Curr Opin Chem Biol 14(6): 790-6 (2010)

PubChem as a public resource for drug discovery.
[20970519] Drug Discov Today 15(23-24): 1052-7 (2010)

Exploiting PubChem for Virtual Screening.
[21691435] Expert Opin Drug Discov 5(12): 1205-1220 (2010)

Successful drug development despite adverse preclinical findings part 2: examples.
[22272032] J Toxicol Pathol 23(4): 213-34 (2010)

Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findings.
[22272031] J Toxicol Pathol 23(4): 189-211 (2010)

Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations.
[21041384] Mol Cancer Ther 9(12): 3137-44 (2010)

Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery.
[21129975] Trends Microbiol 19(2): 65-74 (2011)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Drug development.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Drug development.php on line 92